Related Experiment Video
Updated: May 25, 2026
Fluorescent Lateral Flow Immunoassay Based on Quantum Dots Nanobeads
Published on: June 28, 2024
Quantum-dot-based biosensor for simultaneous detection of biomarker and therapeutic drug: first steps toward an assay
Chi Yang1, Chunxiang Xu, Xuemei Wang
1State Key Laboratory of Bioelectronics, School Electronic Science and Engineering, Southeast University, Nanjing, 210096, P. R. China.
Abstract:
Quantitative pharmacology (QP) is often used to study the recommended dose of a drug. Using colorectal cancer as a model, the relationship between exposure (cetuximab, C225, therapeutic drug of colorectal cancer) and the biomarker response (carcinoembryonic antigen, CEA, biomarker of colorectal cancer) is the core for the QP of C225. Thus, simultaneous detection of CEA and C225 is the first step towards an assay for the QP of C225. We developed a quantum dot (QD)-based multi-analyte biosensor for the simultaneous determination of CEA and the corresponding therapeutic drug C225. The assay is based on the competition between a quantum-dots-labeled glycans and target glycans using lectins as the recognition element. The dual-analytic biosensor detected CEA and C225 in the range from 1 ng mL(-1) to 400 μg mL(-1) by stripping voltammetry. The biosensor developed here for the simultaneous detection of the biomarkers and therapeutic drugs is expected to develop as a potential technique for quantitative pharmacology.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
08:34A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening
Published on: October 16, 2015
Related Concept Videos
01:20Measurement of Bioavailability: Pharmacodynamic Methods
01:26Therapeutic Drug Monitoring: Drug Analysis Methods